术前抗纤溶药与血管手术后输血减少相关
该多医院回顾性队列纳入674例择期大型血管手术患者,31.6%术前60分钟内接受抗纤溶药。
要点
- 择期大型血管手术术前使用抗纤溶药与术后5天输血量减少独立相关。
- 术前抗纤溶药未增加静脉血栓栓塞、出血并发症或旁路血栓形成风险。
- 癫痫仅见于未接受抗纤溶药的患者,住院期间无卒中发生。
核心结论
- 择期大型血管手术术前给予抗纤溶药与术后5天内输血量减少相关,且未观察到明显安全性问题。
研究设计与样本
- 多医院卫生系统回顾性队列研究,纳入2017年1月至2024年6月择期大型腹部血管重建及下肢旁路手术成人患者674例。
- 术前抗纤溶药定义为麻醉记录手术开始前60分钟内给予氨甲环酸或ε-氨基己酸。
- 主要结局为术后5天内输注血制品总量,采用多变量负二项回归分析并以术者聚类方差。
主要发现
- 674例患者年龄68.6±10.8岁,男性67.4%,白人88.1%,213例(31.6%)接受术前抗纤溶药。
- 接受抗纤溶药患者中36例(16.9%)术后5天内输血,每人中位2个血制品(IQR 1-2)。
- 癫痫仅见于未接受抗纤溶药患者(n=2),静脉血栓栓塞、出血并发症及旁路血栓形成发生率两组相似。
临床怎么用
- 对于择期大型血管手术患者,可考虑术前60分钟内给予抗纤溶药以减少术后输血需求。
- 术前使用抗纤溶药时仍需关注癫痫、静脉血栓栓塞、出血及旁路血栓形成等安全性结局。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Major vascular surgery interventions are critical for treating peripheral artery disease but carry a high risk of intraoperative blood loss with resultant coagulopathy. Blood product transfusions are limited, costly, and associated with an increased risk of myocardial infarction and death. Planned preoperative administration of antifibrinolytic agents (AFAs), aimed at inhibiting intraoperative plasmin-mediated lysis, has become a standard practice for orthopedic, trauma, obstetrics, and cardiac surgery, effectively reducing the perioperative bleeding and transfusion requirements. However, there are limited data that support AFA use in vascular surgery interventions. We hypothesize that preoperative AFA administration in elective major vascular surgical interventions is associated with reduced receipt of blood products. METHODS: We included elective, index major abdominal revascularization procedures (open abdominal aortic aneurysm repair, mesenteric revascularization, and aortoiliac revascularization) and lower extremity revascularization procedures (open bypass) in adult patients across a multihospital health care system (January 2017-June 2024). Preoperative AFA use (tranexamic acid or epsilon-aminocaproic acid) was defined as administration within 60 minutes of the operative start time recorded in anesthesia logs. The primary outcome was total blood product transfusions received (packed red blood cells, fresh frozen plasma, platelets, or cryoprecipitate) within 5 postoperative days. Safety outcomes included inhospital seizures, venous thromboembolism events (VTEs; deep venous thrombosis, pulmonary embolism), arterial thrombosis (stroke, bypass thrombosis), and bleeding complications. Multivariable negative binomial regression was used to analyze the association between preoperative AFAs and the number of postoperative blood transfusions with clinically significant covariates selected a priori with variance clustering by surgeon. RESULTS: Among 674 patients (aged 68.6 ± 10.8 years, male 67.4%, and White 88.1%), 213 (31.6%) received preoperative AFAs. Among treated patients, 36 (16.9%) received blood transfusion by postoperative day 5 at a median of 2 [IQR, 1-2] products per person. After covariate adjustment, preoperative AFA use was significantly associated with fewer blood products transfused by 5 postoperative days (adjusted incident rate ratios [aIRR], 0.57; 95% CI, 0.34-0.98; P =.04). Seizures were only observed among patients who did not receive preoperative AFAs (n = 2). Rates of VTE, bleeding complication, and bypass thrombosis were similar with and without AFA exposure (VTE: n = 2 [0.9%] vs n = 5 [1.1%]; P = .86; bleeding: n = 3 [1.4%] vs n = 6 [1.3%]; P > .9; bypass thrombosis: n = 7 [3.3%] vs n = 11 [2.4%]; P = .7). There were no inhospital strokes. CONCLUSIONS: Overall, preoperative administration of AFAs was associated with a decreased number of transfusions at 5 postoperative days without notable safety concerns after major vascular interventions. These findings suggest a potential benefit of including preoperative AFA administration as the standard of care for patients undergoing major vascular surgery.
引用
- Lowenkamp MN, Kim SE, Nassereldine H, et al. Association of preoperative antifibrinolytics with reduced blood transfusions after vascular surgery procedures. J Vasc Surg. 2026. PMID: 42019561. doi:10.1016/j.jvs.2026.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。